Business Context and Reporting Period
Company: Immunovant, Inc. (IMVT)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended June 30, 2026
Business Overview: Immunovant is a clinical-stage immunology company focused on developing IMVT-1402 (imeroprubart), a next-generation anti-FcRn antibody for autoimmune diseases. In April 2026, the Company discontinued the development of its first-generation asset, batoclimab, to concentrate resources on IMVT-1402.
Key Financial Metrics
| Metric | Q1 2026 (Three Months Ended June 30) | Q1 2025 (Three Months Ended June 30) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(153.2) million | $(120.6) million |
| Net Loss Per Share (Basic & Diluted) | $(0.75) | $(0.71) |
| Operating Expenses | $160.3 million | $127.2 million |
| Research & Development (R&D) | $142.6 million | $101.2 million |
| General & Administrative (G&A) | $17.7 million | $26.0 million |
| Interest Income, Net | $7.1 million | $6.3 million |
| Cash and Cash Equivalents (End of Period) | $797.8 million | $598.9 million |
| Net Cash Used in Operating Activities | $(124.4) million | $(117.4) million |
| Accumulated Deficit | $(1,898.4) million | $(1,360.1) million |
Material Changes vs. Prior Period
- Increased R&D Spend: R&D expenses rose $41.4 million (41%) year-over-year. This increase was driven by higher therapeutic area-specific costs, particularly in endocrine diseases (+$23.6M) and rheumatology (+$14.1M), reflecting the expansion of IMVT-1402 clinical trials. These increases were partially offset by the wind-down of batoclimab trials.
- Decreased G&A Spend: G&A expenses declined $8.3 million (32%), primarily due to lower personnel-related expenses (including a one-time stock-based compensation charge in the prior year related to a former CEO's retirement) and reduced professional fees.
- Strategic Pivot: The Company formally discontinued batoclimab development in April 2026 following Phase 3 results in thyroid eye disease that did not meet primary endpoints. This decision shifted focus entirely to IMVT-1402.
- Cash Position: Cash balances decreased by $104.3 million during the quarter, primarily due to operating cash outflows, though the Company maintains a strong liquidity position with nearly $800 million in cash.
Guidance, Outlook, and Risks
Outlook and Guidance: Management expects existing cash of $797.8 million to fund operations through the potential commercial launch of IMVT-1402 in Graves' disease (GD). The Company is evaluating potential expansions of its development plans following positive preliminary results in difficult-to-treat rheumatoid arthritis (D2T RA). Updated cash runway guidance is expected after top-line results from Period 2 of the D2T RA and cutaneous lupus erythematosus (CLE) trials later in the year.
Clinical Progress:
- D2T RA: Positive preliminary Week 16 results showed 72.7% ACR20 response in a heavily pretreated population.
- Pipeline: Ongoing trials in GD, D2T RA, Myasthenia Gravis (MG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Sjögren's disease (SjD), and CLE.
Risks and Contingencies:
- Capital Needs: The Company has no revenue and expects to incur losses for the foreseeable future. Additional capital will be required to complete development and commercialization.
- Contractual Commitments: As of June 30, 2026, the Company has $42.5 million in non-cancelable contractual costs accrued from the batoclimab discontinuation and a new $22.8 million minimum commitment for IMVT-1402 manufacturing.
- License Agreement: Potential future milestone payments of up to $420 million remain contingent on regulatory and sales milestones under the HanAll Agreement. Discussions regarding the disposition of batoclimab rights are ongoing.
- Interim Data Risk: Preliminary clinical data are subject to change upon full analysis and audit.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $797.8 million cash balance against the projected timeline for IMVT-1402 commercial launch and potential expansion of clinical programs.
- Batoclimab Wind-down: Confirm the status of the $42.5 million accrued liability and any potential disputes or additional costs related to the discontinuation of batoclimab and the HanAll Agreement.
- IMVT-1402 Manufacturing: Review the $22.8 million minimum commitment for drug substance manufacturing and the variable cost components tied to inflation and raw materials.
- Clinical Trial Timelines: Monitor the expected top-line result dates for GD (2027), D2T RA (H2 2026), and CLE (H2 2026) to assess the path to regulatory approval.
- Stock-Based Compensation: Note the reduction in stock-based compensation expense ($13.5M vs $18.4M prior year) and its impact on future expense projections as headcount stabilizes.